clinical trial · NCT04857957
Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
Painful Diabetic NeuropathyOral dose CNTX-6016 or oral dose Placebo
brief summary
A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
started
Apr 14, 2021
primary completion
Aug 30, 2023
completion
Aug 30, 2023
last updated
Jul 28, 2025
official title
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CNTX-6016 in Healthy Subjects and a Single Cohort of Subjects With Painful Diabetic Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol